Finzati - Logo
PKTX logo

ProtoKinetix, Incorporated

PKTXBiotechnology
$0.00
0.00 (0.00%)
Current price
EarningsLatest report: Sep 30, 2025
WEAK PROFILEWeakConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$77,889.943
Growth
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0Weak profitability
Financial data as of: Sep 30, 2025, 12:00 AM UTCLast earnings update: Sep 30, 2025, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.00
Change0.00%
Shares Out389.45M
Market Cap$77.89K
Enterprise Value$77.28K
52W Range0.00 - 0.01
Beta0.75
P/E-0.21
P/S1.60
P/B0.31
P/FCF-0.42
EV/Sales1.59

Investment DNA

How strong this company looks for long-term investors

27
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
20/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
20/100
Why this score
Manageable debt level · 0Weak profitability
Analyst view
No analyst data available now.

Company Overview

IPO: 4/22/2002
Industry: Biotechnology
P/B i: 0.31
Debt / Equity i: 0.00
Operating Margin: 0.00%
Net Margin: 0.00%
ROE i: -
ROIC: -

Financial Health

Score4 / 20
Debt / Equity: 0.00
Current Ratio: -0.03
Quick Ratio: -0.03
Status: HighRisk

Insider Transactions

Recent executive and insider activity

2 high-volume insider sells detected
Jones Michael Winston
Transaction: 06/17/2026
OTHER
Change
0
Price
Not reported
Filing
06/24/2026
Type
OTHER
SMITH CLARENCE EDWARD
Transaction: 09/26/2024
BUY
Change
+2,000,000
Price
$0.01
Filing
09/27/2024
Type
BUY
SMITH CLARENCE EDWARD
Transaction: 06/14/2024
BUY
Change
+3,100,000
Price
$0.01
Filing
06/17/2024
Type
BUY